Ascendis Pharma A (ASND) Retained Earnings (2012 - 2017)

Ascendis Pharma A has reported Retained Earnings for 8 years, with the latest figure at -$22.7 million in Q4 2020.

• Quarterly Retained Earnings fell 26.46% year-over-year to -$22.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$22.7 million (down 26.46% YoY) and the FY2020 annual result came in at -$22.7 million, down 24.98% from the prior year.
• Retained Earnings declined to -$22.7 million in Q4 2020 per ASND's latest filing, from -$18.0 million in the prior quarter.
• Over five years, Retained Earnings peaked at $208.3 million in Q3 2017 and troughed at -$22.7 million in Q4 2020.
• A 4-year average of $94.7 million and a median of $100.1 million in 2016 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2016 and 2017: Retained Earnings sank 51.28% in 2016, then surged 211.87% in 2017.
• Over 4 years, Retained Earnings stood at $172.0 million in 2016, then rose by 21.16% to $208.3 million in 2017, then slumped by 108.62% to -$18.0 million in 2019, then fell by 26.46% to -$22.7 million in 2020.
• According to Business Quant data, Retained Earnings over the past three periods registered -$22.7 million, -$18.0 million, and $208.3 million for Q4 2020, Q4 2019, and Q3 2017 respectively.